Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
14.45
-0.27 (-1.83%)
At close: Apr 3, 2025, 4:00 PM
14.43
-0.02 (-0.14%)
After-hours: Apr 3, 2025, 5:09 PM EDT
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$640,300
Profits / Employee
$86,400
Market Cap
3.73B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OGN News
- 2 days ago - Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Business Wire
- 6 days ago - European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - Business Wire
- 16 days ago - Why Organon Is A Top Pick For Income Investors - Seeking Alpha
- 26 days ago - New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older - Business Wire
- 6 weeks ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
- 6 weeks ago - Organon: 7% Yield With A Bargain Basement Valuation - Seeking Alpha
- 7 weeks ago - Organon & Co. (OGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Business Wire